Posted by Michael Wonder on 19 May 2020
FDA appears to soften stance on hydroxychloroquine after Trump says he takes malaria drug
19 May 2020 - The U.S. FDA said Tuesday that taking hydroxychloroquine is “ultimately” a choice between patients and their health-care providers, appearing to soften its earlier advisory against taking the anti-malaria drug outside of a hospital.
“The decision to take any drug is ultimately a decision between a patient and their doctor,” FDA Commissioner Dr. Stephen Hahn said in a statement to CNBC.
“Hydroxychloroquine and chloroquine are already FDA-approved for treating malaria, lupus, and rheumatoid arthritis.”
